A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Trodusquemine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 15 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 15 Aug 2017 Status changed from recruiting to suspended as treatment schedule revision is pending.